Clinical Trial Update: Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)

View source ↗

Summary

An update on a clinical trial examining progression of mild to moderate idiopathic pulmonary fibrosis in patients treated with pirfenidone (Esbriet). The report…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Esbriet (pirfenidone)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Idiopathic Pulmonary Fibrosis | Status: COMPLETED